Preoperative clinical radioimmunodetection of pancreatic cancer by In-111-labeled chimeric monoclonal antibody Nd2

The present study was carried out with the purpose of evaluating the clinic al usefulness of radioimmunodetection (RAID) with In-111-labeled murine/hum an chimeric monoclonal antibody, Nd2 (c-Nd2) in patients with pancreatic ca ncer. Nineteen patients suspected to have pancreatic cancer were administer ed intravenously 74 MBq/2 mg In-111-Iabeled c-Nd2 in 100 ml of saline conta ining 2% albumin over 30 min. A scintigram was obtained on the 3rd day afte r infusion by using single photon emission computed tomography (SPECT) imag ing. Of the 14 patients finally diagnosed as having pancreatic cancer on th e basis of surgical specimens or progress of disease, specific focal uptake at the site of the tumor was detected in 12 (true positive cases), represe nting a sensitivity of 85.7% (12/14), and liver metastasis was found in one case with metastasis. Of the 5 patients diagnosed with tumor-forming pancr eatitis (TFP), 4 patients demonstrated true negative imaging, but one patie nt whose tumor demonstrated interesting findings in histology and immunosta ining, showed false positive imaging. Of patients investigated for human an ti-chimeric antibody (HACA) response, none showed HACA response, and no all ergic reaction was seen in any of the patients administered c-Nd2. These re sults suggest that RAID with In-111-labeled c-Nd2 is useful for differentia l preoperative diagnosis between invasive pancreatic cancer and TFP.